Market News AIOpen the app

Wells Fargo changed its rating for Praxis Precision Medicines to Overweight and set a price target of $509.

OpinionRead the original at marketscreener.com
Good for PRAX

Wells Fargo moved its Praxis rating from Equalweight to Overweight and set a $509 share-price target. That supports a favorable read, though the report gives no new trial or sales results.

PRAX · Praxis Precision Medicines, Inc.

AI read · Good for PRAX

The AI's read

A stronger analyst view can help investors see more promise in Praxis. But the report does not say that a treatment trial or the company's sales changed.

Get alerts for PRAX

Follow Praxis Precision Medicines, Inc. (PRAX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PRAX
Free on the App Store and Google Play, or on the web.